HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NU SKIN MUST SUPPORT PRODUCT CLAIMS WITH "COMPETENT AND RELIABLE EVIDENCE,"

This article was originally published in The Rose Sheet

Executive Summary

NU SKIN MUST SUPPORT PRODUCT CLAIMS WITH "COMPETENT AND RELIABLE EVIDENCE," including scientific data "when appropriate," under a proposed consent agreement with the Federal Trade Commission (FTC) announced Jan. 10. The agreement prohibits the multi-level marketing company from "making any representation, directly or by implication, regarding the performance, benefits, efficacy or safety of any product or service...unless at the time of making such representation," the firm or its representatives "possess and rely upon competent and reliable evidence, which when appropriate must be competent and reliable evidence, that substantiates the representation."

You may also be interested in...



OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review

Topics

UsernamePublicRestriction

Register

RS000060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel